Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPItello-281: capivasertib + abiraterone versus placebo + abiraterone in PTEN-loss metastatic hormone-sensitive prostate cancer
CTR20202619Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capivasertib in prostate cancer (PCa), sponsored by AstraZeneca. Started Jun 2022; status: active.
02
Drugs
capivasertib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20202619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202619.